Press Releases / Company News

Nodality, Inc. Announces Publication of Promising Data in Melanoma in Journal of Translational Medicine

May 28, 2014

Nodality, Inc. announced today promising data utilizing the company's proprietary Single Cell Network Profiling (SCNP) technology in metastatic melanoma. Read more…

Nodality Appoints Ralph Snyderman, M.D., to Board of Directors

February 26, 2014

Nodality, Inc. announced today the appointment to the Company's Board of Directors of Ralph Snyderman, M.D., Chancellor Emeritus at Duke University and James B. Duke Professor of Medicine. Read more…

Nodality Enters into a Strategic Collaboration with Johnson & Johnson Innovation in Autoimmune Diseases

January 08, 2014

Nodality, Inc. announced today a strategic collaboration facilitated by the Johnson & Johnson Innovation Center in California under an agreement with Janssen Biotech, Inc. (“Janssen”) to apply Nodality's proprietary Single Cell Network Profiling (SCNP) technology to immunology R&D programs. Read more…

Nodality, Inc. Announces Presentations at the 28th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

November 12, 2013

Nodality, Inc. announced today promising data utilizing the company's proprietary Single Cell Network Profiling (SCNP) technology in metastatic melanoma. Read more…

Nodality, Inc. Announces Presentations at 2013 American College of Rheumatology Annual Meeting

October 28, 2013

Nodality, Inc. announced promising data utilizing the company's proprietary Single Cell Network Profiling (SCNP) technology in rheumatoid arthritis. Read more…

Nodality, Inc. Reports Promising Rheumatoid Arthritis Study Results to Predict Patient Treatment Response to TNF Inhibitors

August 26, 2013

Nodality, Inc. announced today results of the Company's comprehensive research study to identify cell markers (biomarkers) of disease activity and treatment success in rheumatoid arthritis (RA) patients. Read more…

Nodality, Inc. Announces Data Presentations at AACR 2013 Annual Meeting

April 11, 2013

Nodality, Inc. announced today results of the Company's Single Cell Network Profiling (SCNP) technology as reported in two poster presentations at the 104th Annual Meeting of the American Association for Cancer Research (AACR), held in Washington, DC this week. Read more…

Nodality, Inc. Announces Expansion of Company's Patent Estate Covering Programs to Improve the Treatment of Patients with Severe Diseases in Immunology, Oncology, and Autoimmune Diseases

April 09, 2013

Nodality, Inc. announced today the issuance by the United States Patent and Trademark Office (USPTO) of Patent Number 8,394,599, which broadly covers methods for applying the Company's Single Cell Network Profiling (SCNP) technology. Read more…

Nodality, Inc. Expands Senior Team, Appoints Guy Cavet, Ph.D., as Chief Information Officer, Head of Computational Sciences

March 04, 2013

Nodality, Inc. announced today the appointment of Dr. Guy Cavet as Chief Information Officer and Head of Computational Sciences, effective immediately. Read more…

Nodality, Inc. Appoints Laura Brege as Chief Executive Officer

September 24, 2012

Nodality, Inc. announced today the appointment of senior industry veteran Laura A. Brege as President and Chief Executive Officer, effective immediately. Read more…

Nodality Enters into a Multi-Year Strategic Collaboration with Pfizer in Autoimmune Disease

August 09, 2012

Nodality, Inc. today announced a strategic collaboration with Pfizer Inc. for the use of Nodality's proprietary Single Cell Network Profiling (SCNP) technology as a tool for the development of Pfizer compounds. Read more…

Nodality Receives Three Key US Patents in Oncology and Autoimmune Diseases

July 24, 2012

Nodality, Inc. received three, key patents from the United States Patent and Trademark Office (USPTO). Read more…

Nodality, Inc. Raises $15M in New Funding

July 17, 2012

Nodality, Inc. today announced that it has raised an additional $15 million in financing. Read more…

Nodality, Inc. Receives CLIA Certification for its Clinical Laboratory

June 28, 2012

Nodality, Inc. today announced certification from the U.S. Department of Health and Human Services' Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 for its clinical laboratory in South San Francisco, California. Read more…

Nodality and UCB Enter into a Multi-Year Strategic Collaboration

February 10, 2012

Nodality, Inc. and UCB Pharma S.A. today announced a strategic collaboration utilizing Nodality's proprietary Single Cell Network Profiling (SCNP) technology to assist the development of several UCB compounds. Read more…

Nodality, Inc. Appoints Daniel Dornbusch as Vice President of Business Development

August 01, 2011

Nodality, Inc. announced today that it has appointed Daniel Dornbusch as Vice President of Business Development. Read more…

Nodality, Inc. Appoints Michael Goldberg as Executive Chairman of the Board of Directors

June 01, 2011

Nodality, Inc. announced today that it has appointed Michael Goldberg as Executive Chairman of its Board of Directors. Read more…

Nodality Takes Top Honors as “Most Promising Company” at the Personalized Medicine World Conference 2011

January 24, 2011

Silicom Ventures LLC, producer and co-host of the Personalized Medicine World Conference 2011 held January 18th and 19th, today announced that Nodality, Inc. was selected for the conference's “Most Promising Company” award. Read more…

Nodality Appoints Dr. Greg Critchfield to Board of Directors

December 13, 2010

Nodality, Inc. today announced that Gregory Critchfield, M.D., M.S., has joined the company's Board of Directors. Read more…

Nodality Showcases Novel, Proprietary Technology to Predict Response to Therapy and Relapse Risk in Cancer Patients

December 07, 2010

Nodality, Inc. today announced the presentation of promising data related to the application of the company's novel, proprietary technology, Single Cell Network Profiling (SCNP) in hematologic malignancies. Read more…

Nodality Announces Presentations at 2010 ASH, Including Key Findings in Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL)

November 29, 2010

Nodality, Inc. today announced presentation of promising data related to the application of the company's novel, proprietary technology, Single Cell Network Profiling (SCNP) in hematologic malignancies. Read more…

Nodality and Celgene Form Drug Development Collaboration

July 16, 2010

Nodality, Inc. today announced a collaboration with Celgene Corporation to support early stage clinical drug development. Read more…

Nodality Completes $15.5 Million in Financing

March 22, 2010

Nodality, Inc. today announced it completed financing in which the company raised $15.5 million. Read more…

Nodality Announces Data Presentations at 2009 ASH

November 30, 2009

Nodality, Inc. will present seven abstracts at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA. Read more…

Nodality Completes Series B Financing

March 16, 2009

Nodality, Inc. announced it has completed a $20 million Series B funding. Read more…

Nodality Names David R. Parkinson, M.D. as Its CEO

September 24, 2007

Nodality, Inc. today announced the appointment of David R. Parkinson, M.D., the former senior medical officer at Biogen Idec, as its first president and chief executive officer. Read more…

Nodality Raises Series A Financing

February 01, 2007

Nodality, Inc. today announced it has raised $11.1 million in Series A financing, with proceeds from Kleiner Perkins Caulfield & Byers and TPG Biotechnology. Read more…